Showing 119 of 119on this page. Filters & sort apply to loaded results; URL updates for sharing.119 of 119 on this page
DLL3 trispecific binds to CD3 and CD137 competitively. A, Activation of ...
Assessment of DLL3 and CD3 Expression in Pediatric Tumor FFPE Samples ...
Henlius’ DLL3 × CD3 × CD28 Tri-specific TCE: An Integration of ...
DLL3 – A Breakthrough Target for Small Cell Lung Cancer Therapy-DIMA ...
Anti-DLL3(tarlatamab without CD3 biosimilar) mAb-DLL3阳性参照抗体-适用于Flow Cyt ...
Dll3 Protein Atlas at Bryan Riggs blog
DLL3 regulates Notch signaling in small cell lung cancer: iScience
Immunotherapeutic Targeting and PET Imaging of DLL3 — Chou Lab @ UCSF
Full article: Phase I trial of the DLL3/CD3 bispecific T-cell engager ...
1.7亿美元首付：第一三共从默沙东引进一款DLL3/CD3双抗_财富号_东方财富网
Mechanism of Action (MOA) | IMDELLTRA® (tarlatamab-dlle) HCP
DLL3/CD3 T-cell engager | InOncology – Boehringer Ingelheim
勃林格殷格翰小细胞肺癌新药DLL3/CD3双抗II期临床试验在中国获批-美通社PR-Newswire
安进大胜「肺癌之王」
重磅！Amgen首创双抗Tarlatamab (CD3+DLL3)获批上市 - 知乎
2022 WCLC | 靶向DLL3/CD3双抗Tarlatamab治疗SCLC的I期数据更新医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
ASCO GU 2026: Efficacy and Safety of the DLL3/CD3 T-Cell Engager ...
读书报告 | 靶向DLL3和CD3+T细胞的双特异性Tarlatamab治疗复发性小细胞肺癌的I期临床研究-MedSci.cn
突破：首个实体瘤TCE双抗获批上市 今日，Amgen宣布，FDA加速批准其靶向DLL3/CD3的双特异抗体tarlatamab上市，用于治疗 ...
DLL3/CD3 bispecific antibody: mechanism of action - YouTube
Delta‐like ligand 3: A promising target against small cell lung cancer ...
Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell ...
Tarlatamab Biosimilar Antibody (Recombinant DLL3-CD3 BiTE-class ...
2023 WCLC | 小细胞肺癌的探索：DLL3靶向药物，B7-H3 ADC 小细胞肺癌（SCLC）约占肺癌的14%，且预后不良，广泛期患者 ...
Frontiers | Advances in DLL3-targeted therapies for small cell lung ...
二线大胜：安进启动DLL-3/CD3双抗第2项小细胞肺癌一线三期临床
Anti-DLL3 and CD3(tarlatamab biosimilar) BsAb
Taking a Bite Out of Small Cell Lung Cancer By Leveraging Precision ...
DLL3：多赛道进击小细胞肺癌 - 知乎
靶向DLL3，安进/百济神州递交双特异性T细胞结合器临床申请 3月15日，中国国家药监局药品审评中心（CDE）官网公示， 安进 （Amgen ...
Combined DLL3-targeted bispecific antibody with PD-1 inhibition is ...
记住所有FDA生物药 | DLL3×CD3双抗 | Tarlatamab 塔拉塔单抗 | 广泛期小细胞肺癌 - 知乎
针对小细胞肺癌靶向DLL3的新疗法-MedSci.cn
Bispecific T cell engager (BiTE) tumor killing assay I CRO Immuno-Oncology
Pharmacokinetics and pharmacodynamics of Tarlatamab, DLL3-Targeted FDA ...
实体瘤突破：安进DLL3/CD3双抗获FDA批准 Armstrong 2024年5月16日，FDA加速批准 安进 DLL3/CD3双抗 ...
安进DLL3/CD3双抗获FDA批准上市医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
安进/百济神州DLL3/CD3双抗在华申报临床 3月15日， 安进 递交Tarlatamab的临床试验获得CDE受理。Tarlatamab ...
【疗效显著】安进DLL3/CD3双抗临床3期取得重大突破 - 知乎
A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces ...
DLL3/CD3 T-cell Engager | Clinical Research | InOncology
塔拉妥单抗(TARLATAMAB-DLLE) - 药物靶点：CD3 x DLL3_在研适应症：小细胞肺癌，广泛期小细胞肺癌，局限期小细胞肺癌 ...
[PDF] A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces ...
AACR 2025: Preclinical evaluation of CD3/DLL3 bispecific antibody in ...
安进宣布DLL3/CD3双抗上市申请获FDA优先评审资格医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Targeting DLL3: Innovative Strategies for Tumor Treatment
安进：DLL3/CD3双抗递交上市申请，获优先审评资格 Armstrong 2023年12月13日， 安进 宣布DLL3/CD3双抗 ...
Biocytogen's DLL3×CD3×4-1BB TriAb: A New Path for TCE Therapies ...
用于治疗癌症的DLL3/CD3结合蛋白的制作方法
广泛期小细胞肺癌迎来靶向新药，DLL3/CD3双抗「塔拉妥单抗」国内上市 - 知乎
Obrixtamig Could Broaden the Reach of DLL3/CD3-Targeted BiTEs in Small ...
DLL3: A New Molecular Target in Cancer - Cusabio
Promising Activity in DLL3-Positive SCLC and NECs with a Novel ...
小细胞肺癌的治疗靶点DLL3
TCE In Vitro Evaluation Platform: Comprehensive Assessment from Target ...
Frontiers | Harnessing delta-like ligand 3: bridging biomarker ...
2024年第一大药物机会_财富号_东方财富网
Anti-DLL3-Anti-CD3 Bispecific Molecule
Bispecific Antibody - BiCell Scientific®
勃林格殷格翰：DLL3/CD3启动一线小细胞肺癌三期临床 Armstrong 2026年3月16日，勃林格殷格翰在Clinicaltrials ...
热门靶点组合策略CD3×TAA - 知乎
Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in ...
Assessment of DLL3/CD3 T-cell Engager Obrixtamig for Neuroendocrine ...
DLL3靶点介绍及药物研究进展-缔码生物
Obrixtamig | DLL3/CD3 Cytolytic Synapse | InOncology
CD3双抗：肿瘤治疗的突破与自免领域的新机遇
AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager ...
DLL3：多赛道进击小细胞肺癌 DLL3概述Delta样配体3 (Delta-Like Ligand 3, DLL3)是Notch配体家族的 ...
DLL3: Emerging Target in Tumor Therapy Treatment Strategies | KACTUS
首个针对DLL3表达肿瘤的三抗：泽璟制药ZG006的临床试验申请获得FDA批准
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients ...
NCT04429087 (1438-0001) | InOncology – Boehringer Ingelheim
